Michael Shusterman, MD
@guildsman
Followers
817
Following
340
Statuses
1K
GI Medical Oncologist @Perlmutter_CC, Associate Program Director @nyulisom_HemOnc. Tweets my own. #Meded
Mineola, NY
Joined August 2009
“A clinical trial with randomization to a variety of treatment doses and schedules is required to investigate the optimal amounts of chemotherapy patients should receive both preoperatively and in the postoperative setting.”
Dose density 🔋 in #neoadjuvant Tx for #PDAC A landmark analysis of @SWOG S1505 DD >85% pre or DD >70% periop ➡️OS benefit Kudos 👏🏽 to investigators and lead author Dr. Sameer Patel @UCincySurg
@SyedAAhmad5 @DavendraSohal
@OHSUKnight @OHSUpancreatic
0
0
3
RT @jryckman3: 🚀 The SOFT trial is packed with fascinating insights! Let’s dive into the details 🧵 ⬇️ #radonc…
0
8
0
RT @OncoThor: Can the therapy of grade 3 neuroendocrine neoplasms be distilled down to a single slide? Not sure, but here is my attempt for…
0
48
0
RT @RManochakian: 🔥🚨HOT OFF THE PRESS Just published @JCO_ASCO IMPORTANT SPECIAL ARTICLE & #Recommendations for #Academic #MedicalCenters…
0
29
0
RT @NiuSanford: New YouTube video by request 😀 Rad Onc 101! 10 min overview of rad onc: dosing, terminology, etc. Non rad oncs: promise y…
0
55
0
RT @KrishanJethwa: 🚨COLLISION Trial🚨 🔍Thermal ablation vs resection for #crc liver mets </= 3 cm 🛑 for meeting predefined rules with goal t…
0
12
0
RT @PsyOnc: A tailored stress management program for scanxiety in patients w advanced lung cancer demonstrated high acceptability, feasibil…
0
2
0
RT @Erman_Akkus: 📘Treatment of dMMR/MSI gastro-oesophageal adenocarcinoma @myESMO @EORTC ✅Excellent review from biology to management 👉h…
0
62
0
Excellent talk about hospital based medicine with suggestions for @NYULISOM_HemOnc to use in seeing patients in the inpatient setting.
🚨 This week’s #UCSFMGR, Sam Brondfield, MD (@s_brond), discusses how the Hospital-Based Oncology (HBO) team is transforming oncology care within the hospital setting. Moderated by @Bob_Wachter. 🎥 Watch now:
0
1
2
@manjuggm Nearly all of our false negative ctDNA issues have been lung metastases and as soon as we see a new / enlarging nodule we monitor even more closely.
0
0
1
@agrothey Agreed, but even after our JNCCN study, we are still convincing many colleagues to at least drop bolus. Not sure what level of evidence we need when no one is going to fund a Phase III trial of dropping the bolus.
1
1
6
@manjuggm Also our group needs 15 min minimum to explain pre-and post-adj Rx what ctdna means including false neg, impact on surveillance, etc. Not sure if most patients having this type of complex discussion prior to test being drawn? Worth a survey study I think? Colontown interested?
1
0
1
RT @GIcancerDoc: @MyriamChalabi @TheLancet @sara_lonardi1 @bmsnews Except we still do not have the 1L H2H data understanding (statistical…
0
1
0
RT @OncBrothers: #GI25 highlights #CommunityOnc: 1. #SCIENCE: Adv Eso SCC 2. #ESOPEC publication (Eso/GEJ/Ga) 3. Chemo in resectable Pa…
0
85
0
RT @GillSharlene: #GI25 @ASCO #LBA🌟 🚨CM8HW in dMMR #mCRC - the awaited nivo/ipi1 vs nivo PFS 🙌 📌 N=707 across all lines, 55% 1L, centrall…
0
50
0
Hoping Phase II and III is available to enroll on soon. We’re ready!
#GI25🎤drop #NEST🪺🙋🏻♂️🙌🏽 |➖➖➖➖➖➖➖➖➖➖ 💯 | | | | | | | | |————————————————— ✅NO RECURRENCES📅! 💡Neoadjuvant immunotherapy keeps delivering! 👉🏽Patients with MSS🧊NOT just MSI-High🔥colorectal #cancer. Goal is to👏🏾*CURE*👏🏾more patients. 🔜Phase2/3 @OncoAlert @ASCO
0
2
8